Osocimab, formerly known as BAY 1213790, represents a unique monoclonal immunoglobulin currently undergoing clinical assessment for the therapy of various hematologic malignancies. This compound selectively targets https://amaanbsrk923276.aboutyoublog.com/52282793/osocimab-a-deep-investigation-into-bay-1213790-and-its-promise